BACKGROUND: @entity1 with metastatic poorly differentiated @entity8703 (PDEC) usually have a short survival. The chemotherapy combination of @entity900 and @entity2879 is frequently used as first-line palliative chemotherapy. There are, however, no published studies concerning second-line treatment of the disease. @entity2903 has shown clinical effect in @entity8703 . This study was performed to evaluate the effect of @entity2903 in PDEC @entity1 who had progressed on first-line treatment. METHODS: Twenty-five @entity1 with PDEC (mainly gastrointestinal) were treated with @entity2903 alone or in combination with @entity416 . A subset of @entity1 also received bevacizumab. @entity8724 methylation was analyzed in tissue specimens. Data were collected retrospectively. RESULTS: One @entity1 had a complete response, and 7 @entity1 had partial response (33% response rate). Median duration of response was 19 months. Another 9 (38%) @entity1 had a stable disease, after progression at inclusion, with a median duration of 18 months. Median progression-free survival for all @entity1 was 6 months, and median overall survival was 22 months. Only 1 @entity1 had a @entity8724 methylation. CONCLUSIONS: Treatment with @entity2903 alone or in combination with @entity416 and bevacizumab resulted in objective response or stabilization in 71% of PDEC @entity1 who failed on first-line chemotherapy. These results indicated that @entity2903 may be used as second-line treatment in PDEC.

Clinical effect of @entity2903 -based chemotherapy in poorly differentiated XXXX after progression on first-line chemotherapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity8703 :: ('MESH:D004701', 'Disease') :: ['endocrine carcinoma', 'well-differentiated endocrine carcinomas'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity8724 :: ('4255', 'Gene') :: ['MGMT'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['Temozolomide', 'temozolomide']
@entity8703 :: (MESH:D004701,Disease) :: ['endocrine carcinoma']
